252 related articles for article (PubMed ID: 28268799)
41. Investigating an alternative ring design of transducer arrays for tumor treating fields (TTFields).
Macedo M; Wenger C; Salvador R; Fernandes SR; Miranda PC
Annu Int Conf IEEE Eng Med Biol Soc; 2016 Aug; 2016():5168-5171. PubMed ID: 28269429
[TBL] [Abstract][Full Text] [Related]
42. Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Stupp R; Taillibert S; Kanner AA; Kesari S; Steinberg DM; Toms SA; Taylor LP; Lieberman F; Silvani A; Fink KL; Barnett GH; Zhu JJ; Henson JW; Engelhard HH; Chen TC; Tran DD; Sroubek J; Tran ND; Hottinger AF; Landolfi J; Desai R; Caroli M; Kew Y; Honnorat J; Idbaih A; Kirson ED; Weinberg U; Palti Y; Hegi ME; Ram Z
JAMA; 2015 Dec; 314(23):2535-43. PubMed ID: 26670971
[TBL] [Abstract][Full Text] [Related]
43. Health-related quality of life, cognitive screening, and functional status in a randomized phase III trial (EF-14) of tumor treating fields with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma.
Zhu JJ; Demireva P; Kanner AA; Pannullo S; Mehdorn M; Avgeropoulos N; Salmaggi A; Silvani A; Goldlust S; David C; Benouaich-Amiel A;
J Neurooncol; 2017 Dec; 135(3):545-552. PubMed ID: 28849310
[TBL] [Abstract][Full Text] [Related]
44. Impact of Peritumoral Edema During Tumor Treatment Field Therapy: A Computational Modelling Study.
Lang ST; Gan LS; McLennan C; Monchi O; Kelly JJP
IEEE Trans Biomed Eng; 2020 Dec; 67(12):3327-3338. PubMed ID: 32286953
[TBL] [Abstract][Full Text] [Related]
45. Tumor-treating fields as a fourth treating modality for glioblastoma: a meta-analysis.
Magouliotis DE; Asprodini EK; Svokos KA; Tasiopoulou VS; Svokos AA; Toms SA
Acta Neurochir (Wien); 2018 Jun; 160(6):1167-1174. PubMed ID: 29696502
[TBL] [Abstract][Full Text] [Related]
46. Using computational phantoms to improve delivery of Tumor Treating Fields (TTFields) to patients.
Bomzon Z; Hershkovich HS; Urman N; Chaudhry A; Garcia-Carracedo D; Korshoej AR; Weinberg U; Wenger C; Miranda P; Wasserman Y; Kirson ED; Yoram
Annu Int Conf IEEE Eng Med Biol Soc; 2016 Aug; 2016():6461-6464. PubMed ID: 28269726
[TBL] [Abstract][Full Text] [Related]
47. Response patterns of recurrent glioblastomas treated with tumor-treating fields.
Vymazal J; Wong ET
Semin Oncol; 2014 Oct; 41 Suppl 6():S14-24. PubMed ID: 25213870
[TBL] [Abstract][Full Text] [Related]
48. Tumor-Treating Fields: Nursing Implications for an Emerging Technology
.
Chang A
Clin J Oncol Nurs; 2017 Jun; 21(3):302-304. PubMed ID: 28524900
[TBL] [Abstract][Full Text] [Related]
49. Planning TTFields treatment using the NovoTAL system-clinical case series beyond the use of MRI contrast enhancement.
Connelly J; Hormigo A; Mohilie N; Hu J; Chaudhry A; Blondin N
BMC Cancer; 2016 Nov; 16(1):842. PubMed ID: 27809808
[TBL] [Abstract][Full Text] [Related]
50. An Overview of Sub-Cellular Mechanisms Involved in the Action of TTFields.
Tuszynski JA; Wenger C; Friesen DE; Preto J
Int J Environ Res Public Health; 2016 Nov; 13(11):. PubMed ID: 27845746
[TBL] [Abstract][Full Text] [Related]
51. Tumour treating fields in a combinational therapeutic approach.
Branter J; Basu S; Smith S
Oncotarget; 2018 Nov; 9(93):36631-36644. PubMed ID: 30564303
[TBL] [Abstract][Full Text] [Related]
52. Acceptance and compliance of TTFields treatment among high grade glioma patients.
Onken J; Staub-Bartelt F; Vajkoczy P; Misch M
J Neurooncol; 2018 Aug; 139(1):177-184. PubMed ID: 29644485
[TBL] [Abstract][Full Text] [Related]
53. Association of Tumor Treating Fields (TTFields) therapy with survival in newly diagnosed glioblastoma: a systematic review and meta-analysis.
Ballo MT; Conlon P; Lavy-Shahaf G; Kinzel A; Vymazal J; Rulseh AM
J Neurooncol; 2023 Aug; 164(1):1-9. PubMed ID: 37493865
[TBL] [Abstract][Full Text] [Related]
54. An Overview of Alternating Electric Fields Therapy (NovoTTF Therapy) for the Treatment of Malignant Glioma.
Swanson KD; Lok E; Wong ET
Curr Neurol Neurosci Rep; 2016 Jan; 16(1):8. PubMed ID: 26739692
[TBL] [Abstract][Full Text] [Related]
55. Heat transfer during TTFields treatment: Influence of the uncertainty of the electric and thermal parameters on the predicted temperature distribution.
Gentilal N; Miranda PC
Comput Methods Programs Biomed; 2020 Nov; 196():105706. PubMed ID: 32818721
[TBL] [Abstract][Full Text] [Related]
56. Tumor treating fields: a comprehensive overview of the underlying molecular mechanism.
Hong P; Kudulaiti N; Wu S; Nie J; Zhuang D
Expert Rev Mol Diagn; 2022 Jan; 22(1):19-28. PubMed ID: 34883030
[TBL] [Abstract][Full Text] [Related]
57. Synergistic inhibition of glioma cell proliferation by Withaferin A and tumor treating fields.
Chang E; Pohling C; Beygui N; Patel CB; Rosenberg J; Ha DH; Gambhir SS
J Neurooncol; 2017 Sep; 134(2):259-268. PubMed ID: 28681243
[TBL] [Abstract][Full Text] [Related]
58. Determining the Optimal Inhibitory Frequency for Cancerous Cells Using Tumor Treating Fields (TTFields).
Porat Y; Giladi M; Schneiderman RS; Blat R; Shteingauz A; Zeevi E; Munster M; Voloshin T; Kaynan N; Tal O; Kirson ED; Weinberg U; Palti Y
J Vis Exp; 2017 May; (123):. PubMed ID: 28518093
[TBL] [Abstract][Full Text] [Related]
59. Anti-cancer mechanisms of action of therapeutic alternating electric fields (tumor treating fields [TTFields]).
Shams S; Patel CB
J Mol Cell Biol; 2022 Dec; 14(8):. PubMed ID: 35973687
[TBL] [Abstract][Full Text] [Related]
60. Alternating electric tumor treating fields for treatment of glioblastoma: rationale, preclinical, and clinical studies.
Mittal S; Klinger NV; Michelhaugh SK; Barger GR; Pannullo SC; Juhász C
J Neurosurg; 2018 Feb; 128(2):414-421. PubMed ID: 28298023
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
